Observational study of haloperidol in hospitalized patients with COVID-19.

Nicolas HoertelMarina Sánchez-RicoRaphaël VernetAnne-Sophie JannotAntoine NeurazCarlos BlancoCédric LemogneGuillaume AiragnesNicolas ParisChristel DanielAlexandre GramfortGuillaume LemaitreMélodie BernauxAli BellamineNathanaël BeekerFrédéric Limosinnull null

Published in: PloS one (2021)

Findings from this multicenter observational study suggest that haloperidol use prescribed at a mean dose of 4.5 mg per day (SD = 5.2) for a mean duration of 8.4 days (SD = 7.2) may not be associated with risk of intubation or death, or with time to discharge home, among adult patients hospitalized for COVID-19.

Keyphrases

coronavirus disease
sars cov
healthcare
cardiac arrest
cross sectional
double blind